Alleged Drug Allergies in Military General Medicine: Patients' Experiences and Beliefs (ALLMED)

October 31, 2023 updated by: Direction Centrale du Service de Santé des Armées

Alleged Drug Allergies in Military General Medicine: Patients' Experiences and Beliefs (ALLMED)

This study focuses on the experience of the military patient reporting a suspected drug allergy, with its own specificities. Suspicions of drug allergies during a mission expose the doctor to difficulties.

This study will improve understanding of the allergy patient's point of view. The end result could be a set of ideas for measures to raise awareness among these patients, and motivate them to undergo an allergological assessment.

Study Overview

Status

Recruiting

Conditions

Intervention / Treatment

Study Type

Observational

Enrollment (Estimated)

20

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult

Accepts Healthy Volunteers

Yes

Sampling Method

Non-Probability Sample

Study Population

Military personnel reporting a drug allergy to antibiotics

Description

Inclusion Criteria:

  • Military personnel (active or reservist)
  • Reporting a drug allergy during a periodic medical check-up or during a consultation in a medical unit
  • Not opposed to participating in the study.

Exclusion Criteria:

  • Candidate on admission visit
  • Opposition to study
  • Minor (under 18 years of age)
  • Pregnant, parturient or breast-feeding woman
  • Person deprived of liberty by a judicial or administrative decision, person under psychiatric care
  • Non-French nationals
  • Person of full age subject to a legal protection measure
  • Person unable to express non-opposition

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
Interview
Monocentric qualitative study with a descriptive socio-demographic section, a descriptive qualitative section on the experience and perception of allergy, then on the obstacles to allergological assessment, and finally a descriptive quantitative section to evaluate knowledge of antibiotic therapy.
Other: Interview
Semi-structured interview on experiences, perceptions, beliefs and knowledge of drug allergy and barriers to allergological testing, with a view to content analysis.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Patients' experiences of drug allergies
Time Frame: Through study completion (12 months)
describe patients' experiences, perceptions, beliefs and knowledge of drug allergies in general practice in the army
Through study completion (12 months)

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Patients' obstacles
Time Frame: Through study completion (12 months)
describe the obstacles to allergological assessment
Through study completion (12 months)

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Direction Centrale du Service de Santé des Armées

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

February 28, 2023

Primary Completion (Estimated)

February 1, 2024

Study Completion (Estimated)

March 1, 2024

Study Registration Dates

First Submitted

October 26, 2023

First Submitted That Met QC Criteria

October 31, 2023

First Posted (Actual)

November 1, 2023

Study Record Updates

Last Update Posted (Actual)

November 1, 2023

Last Update Submitted That Met QC Criteria

October 31, 2023

Last Verified

October 1, 2023

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • 2022PPRC02

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

UNDECIDED

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe